Star Scientific Announces New Directors

Ambassador Carmen was Administrator of the General ServicesAdministration (GSA) from 1981 to 1984, when President Reaganappointed him U.S. Permanent Representative to the United Nations inGeneva with the rank of ambassador. In 1989, he was appointedPresident and CEO of the Federal Asset Disposition Corporation (FADA),the predecessor of the current Resolution Trust Corporation. At thattime FADA managed assets with an estimated aggregate value of $4billion. Prior to his government service, Ambassador Carmen owned achain of automotive stores. Ambassador Carmen currently serves as amember of the Board of Directors of Ezenia, Inc., and chairs the auditcommittee of that board. Other board memberships have included theNortheast Savings Bank, a $9 billion Connecticut bank acquired byFleet; Federal Home Loan Bank Board of Boston; Gruen MarketingCorporation; and Mediplex. He also is a founding partner of Carmen,Carmen and Hugel in Washington, DC, now known as the Carmen Group(www.carmengroup.com), where he currently is a senior consultant. TheCarmen Group's annual revenues places it among the top 25 lobbyingfirms in Washington, DC. A lifelong resident of New Hampshire,Ambassador Carmen served three terms as Chairman of that state'sRepublican Party.

Dr. Chapman is president of Chapman Pharmaceutical Consulting,Inc., which provides expert medical consultation on the developmentand management of domestic and global product development programs forbiotech, pharmaceutical and medical device products. He was SeniorDirector of Medical Affairs with Quintiles/BRI, the largest contractresearch organization (CRO) in the U.S., from 1995-2000. In thatcapacity, Dr. Chapman had oversight responsibility for the support ofnew drug applications (NDA), clinical studies and device submissionsto the FDA for approval. From 1992-1994, Dr. Chapman was MedicalDirector at Regeneron Pharmaceuticals. He currently serves as chairmanof the Chapman Pharmaceutical Health Foundation. He is a graduate ofthe Georgetown University School of Medicine in Washington, DC.

The company also announced that John Bartels, Esquire and WhitmoreB. Kelley have resigned from the Board of Directors after 3 1/2 and 41/2 years of service, respectively. Paul L. Perito, Star's Chairman,President and COO, stated that Star was grateful for the twodirectors' investment of time and energy in the company, particularlyduring a post-Sarbanes Oxley era when the governance burdens ondirectors have increased significantly. In connection with theresignations, the company provided an extension of the period duringwhich those two directors may exercise stock option grants. Generallythe company's stock option agreements provide that upon resignationthe grantee would have a three-month period within which to exerciseoptions. The company agreed to extend the option exercise period forthe departing directors to a maximum of four years, which is withinthe period of the original option grant, and the former directors willprovide consulting service to the company, if requested, during thatperiod.

Mr. Perito also stated that the new directors' combined expertisein public company board service, finance and FDA regulatory expertisebring valuable assets to the oversight of the company's core mission.Jonnie R. Williams, Star's CEO, commented that he looked forward toworking with the new board members as the company continues toactively explore the range of market possibilities for its dissolvablehard smokeless tobacco products, Ariva(R) and Stonewall Hard Snuff(R).The company believes that these products can play an increasinglysignificant role as more municipalities and states enact broadno-smoking laws. Ariva(R), which was introduced in late 2001, wasdeveloped to meet the needs of adult smokers in situations where theycannot or choose not to smoke. Stonewall Hard Snuff(R), introduced inmid-2003, is aimed at adult users of traditional moist snuff, becauseif offers a smokeless tobacco alternative that is "spitless." Bothproducts are made with 100% StarCured(R) tobacco, a tobacco leaf withsharply reduced levels of tobacco specific nitrosamines, considered byresearchers worldwide to be the most important carcinogen in smokelesstobacco.

Safe Harbor Statement

This contains certain forward-looking statements within themeaning of the Private Securities Litigation Reform Act of 1995. TheCompany has tried, whenever possible, to identify theseforward-looking statements using words such as "anticipates","believes", "estimates", "expects", "plans", "intends" and similarexpressions. These statements reflect the Company's current beliefsand are based upon information currently available to it. Accordingly,such forward-looking statements involve known and unknown risks,uncertainties and other factors which could cause the Company's actualresults, performance or achievements to differ materially from thoseexpressed in, or implied by, such statements. These risks,uncertainties and contingencies include, without limitation, thechallenges inherent in new product development initiatives,particularly in the smokeless tobacco area, the uncertainties inherentin the progress of scientific research, the Company's ability to raisethe capital necessary to maintain its business, potential disputesconcerning the Company's intellectual property, risks associated withlitigation regarding such intellectual property, potential delays inobtaining any necessary government approvals of the Company's low-TSNAtobacco products, market acceptance of the Company's new smokelesstobacco products, competition from companies with greater resourcesthan the Company, the Company's decision not to join the MasterSettlement Agreement ("MSA"), the effect of state statutes adoptedunder the MSA and any subsequent modification of the MSA, and theCompany's dependence on key employees and on its strategicrelationships with Brown & Williamson Tobacco Corporation in light ofits combination with RJ Reynolds Tobacco Company, Inc. The impact ofpotential litigation, if initiated against or by individual statesthat have adopted the MSA, could be materially adverse to the Company.

See additional discussion under "Factors That May Affect FutureResults" in the Company's Registration Statement on Form S-3 as filedwith the Securities and Exchange Commission on April 28, 2005, andother factors detailed from time to time in the Company's otherfilings with the Securities and Exchange Commission, available atwww.sec.gov. The Company undertakes no obligation to update or adviseupon any such forward-looking statements to reflect events orcircumstances after the date of this press release or to reflect theoccurrence of unanticipated events.

See Star's website at: http://www.starscientific.com.